Extensive 177Lu-PSMA Radioligand Therapy Can Lead to Radiation Nephropathy with a Renal Thrombotic Microangiopathy

Extensive 177Lu-PSMA Radioligand Therapy Can Lead to Radiation Nephropathy with a Renal Thrombotic Microangiopathy–like Picture

Published:2023-05 Issue:5 Volume:83 Page:385-390
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Schäfer Hannah,Mayr Sarah,Büttner-Herold Maike,Knorr Karina,Steinhelfer Lisa,Böger Carsten A.,Gschwend Jürgen E.,Heemann Uwe,Eiber Matthias,Schmaderer Christoph,Tauber Robert

Publisher

Elsevier BV

Subject

Urology

Reference15 articles.

1. Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer;Heck;Eur Urol,2019

2. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer;Sartor;N Engl J Med,2021

3. Renal outcomes of radioligand therapy: experience of 177lutetium–prostate-specific membrane antigen ligand therapy in metastatic castrate-resistant prostate cancer;Gallyamov;Clin Kidney J,2020

4. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT);Kratochwil;Eur J Nucl Med Mol Imaging,2019

5. The impact of repeated cycles of radioligand therapy using [177Lu]Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer;Yordanova;Eur J Nucl Med Mol Imaging,2017

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PSMA-based therapeutics for prostate cancer;Expert Opinion on Pharmacotherapy;2024-07-02

2. How Can Radiopharmaceutical Therapies Reach Their Full Potential? Improving Dose Reporting and Phase I Clinical Trial Design;Journal of Clinical Oncology;2024-05-20

3. Hematological and renal toxicity in mice after three cycles of high activity [177Lu]Lu-PSMA-617 with or without human α1-microglobulin;Scientific Reports;2024-05-11

4. Safety and Efficacy of Extended Therapy with [¹⁷⁷Lu]Lu-PSMA: A German Multicenter Study;Journal of Nuclear Medicine;2024-05-02

5. Safety and Efficacy ofPara-Aminohippurate Coinfusion for Renal Protection During Peptide Receptor Radiotherapy in Patients with Neuroendocrine Tumors;Journal of Nuclear Medicine;2024-04-18